| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 06/24/2004 | WO2004053120A2 Regulatory elements in the 5' region of the vr1 gene |
| 06/24/2004 | WO2004053101A2 Methods and compositions using compounds from fetal cells and tissues to improve condition of skin |
| 06/24/2004 | WO2004053061A2 Methods of therapy and diagnosis using targeting of cells that express lax |
| 06/24/2004 | WO2004052924A1 Expression of peptides of the cytoplasmic domain of hiv-gp41 for inhibiting viral infections |
| 06/24/2004 | WO2004052402A1 Hypercoiling polymers and their use in cellular delivery |
| 06/24/2004 | WO2004052301A2 Modulation of matrix metalloproteinase 11 expression |
| 06/24/2004 | WO2004052297A2 TREATMENT OF HSV-RELATED PATHOLOGIES USING ssDNA |
| 06/24/2004 | WO2004052276A2 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 06/24/2004 | WO2004052177A2 Cell-based therapies for ischemia |
| 06/24/2004 | WO2004041183A3 Methods of treating pulmonary fibrotic disorders |
| 06/24/2004 | WO2004022716A3 Recombinatant mutants of rhabdovirus and methods of use thereof |
| 06/24/2004 | WO2004000231A3 Methods and compositions for the treament of cancer |
| 06/24/2004 | WO2003076631A3 Genetic products differentially expressed in tumors and use thereof |
| 06/24/2004 | WO2003075856A3 Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phage beta protein, or hydroxyurea |
| 06/24/2004 | WO2003050238A9 Receptor-targeted adenoviral vectors |
| 06/24/2004 | WO2003018044A8 New drug |
| 06/24/2004 | WO2003015613A3 Molecular characteristics of non-small cell lung cancer |
| 06/24/2004 | US20040123337 Method for treating an embryo |
| 06/24/2004 | US20040123336 Using viral particles to improve effectiveness of gene transfer vehicle via inhibition of antigen presenting cells; somatic cell transformation and animal models for disease |
| 06/24/2004 | US20040121992 Therapeutic methods of reducing cholesterol accumulation |
| 06/24/2004 | US20040121976 Anti-inflammatory vectors |
| 06/24/2004 | US20040121973 For therapy of cancer and diabetes |
| 06/24/2004 | US20040121972 Methylenetetrahydrofolate reductase inhibitors and uses thereof |
| 06/24/2004 | US20040121970 Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use |
| 06/24/2004 | US20040121956 For therapy of diseases in animals and for the control of insects that are injurious or harmful to plants or animals |
| 06/24/2004 | US20040121466 Alphavirus RNA replicon systems |
| 06/24/2004 | US20040121434 Comprises mitogen activated kinases kinase fragments for screening and identifying modulators which control cell death; antiapoptosis; antitumor agents |
| 06/24/2004 | US20040121376 Antisense modulation of interleukin-5 signal transduction |
| 06/24/2004 | US20040121372 Comprises receptors for advanced glycation endproduct polypeptides for use in diagnosis and treatment inflammation, infection, sepsis, autoimmune, atherosclerotic and nervous system disorders |
| 06/24/2004 | US20040121348 Compositions and methods for treating pancreatic cancer |
| 06/24/2004 | US20040121327 Method for the prediction of the risk potential for cancerous diseases and inflammatory intestinal diseases and corresponding tests |
| 06/24/2004 | US20040121308 for producing the vectors and suppressing replication/reducing cytotoxicity of vector genome |
| 06/24/2004 | US20040121300 includes a hydroxyethyl starch and/or derivative thereof alone or in combination with either dimethyl sulfoxide (DMSO) or glycerol; for recombinant live cancer cellular vaccine; kits |
| 06/24/2004 | US20040120997 liposomes containing a sterol skeleton based compound wherein one or several amphoteric groups with an isoelectric point of between 4 and 9 are substituted on the 3rd position of the ring system |
| 06/24/2004 | US20040120979 Delivery systems comprising biocompatible and bioerodable membranes |
| 06/24/2004 | US20040120971 Biodegradable carrier and method for preparation thereof |
| 06/24/2004 | US20040120959 administering to a subject with a laminin 5-secreting tumor an amount effective to inhibit tumor growth and/or metastasis of an antibody that binds to one or more epitopes of the laminin 5 gamma 2 chain |
| 06/24/2004 | US20040120954 expression of PEX without a catalytic site of MT1-MMP on a cell surface directly prevents an association of two enzymes and inhibits the activation of proMMP-2 in a dose-dependent manner |
| 06/24/2004 | US20040120952 Anti-TNF antibodies and peptides of human tumor necrosis factor |
| 06/24/2004 | US20040120939 Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use |
| 06/24/2004 | US20040120935 Genetically modified yt cell line and use thereof |
| 06/24/2004 | US20040120933 Pax-encoding vector and use thereof |
| 06/24/2004 | US20040120932 Reprogramming a keratinocyte by treating with agent which promotes demethylation of a nucleic acid; and second agent to inhibit deacetylation of histone protein; reprogrammed cell expresses a telomerase gene |
| 06/24/2004 | US20040120930 Administering mutant epithelial nitric oxide synthase with mutation at a position corresponding to an amino acid residue in a mammalian eNOS that is phosphorylated in mammalian cells; |
| 06/24/2004 | US20040120929 Defective lentivirus pseudotyped with a lyssavirus envelope; selective transfer of genes into astrocytes of central nervous system; nervous system and brain disorders; viral diseases |
| 06/24/2004 | US20040120928 Composite oncolytic herpes virus vectors |
| 06/24/2004 | US20040120899 Methods of treating allergy by administering interleukin-17 receptor |
| 06/24/2004 | US20040120898 Methods of treating asthma by administering interleukin-17 receptor |
| 06/24/2004 | CA2547899A1 Cell-based therapies for ischemia |
| 06/24/2004 | CA2509666A1 Methods and compositions using compounds from fetal cells and tissues to improve condition of skin |
| 06/24/2004 | CA2508204A1 Treatment of hsv-related pathologies using ssdna |
| 06/24/2004 | CA2507156A1 Methods of therapy and diagnosis using targeting of cells that express lax |
| 06/23/2004 | EP1431347A1 Composition containing fine particles for supporting biologically active substance thereon or having the same supported thereon and method for preparing these |
| 06/23/2004 | EP1430903A1 Use of proteasome inhibitors for the treatment of viral infections |
| 06/23/2004 | EP1430157A2 RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS C VIRUS (HCV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 06/23/2004 | EP1430152A2 Gene and protein relating to hepatocellular carcinoma |
| 06/23/2004 | EP1430146A2 Novel nucleic acids and polypeptides |
| 06/23/2004 | EP1430140A2 Isoform-selective inhibitors and activators of pde3 cyclic |
| 06/23/2004 | EP1430137A2 Porcine adenovirus e1 and e4 regions |
| 06/23/2004 | EP1430132A2 Methods of using 33751, a human potassium channel family member |
| 06/23/2004 | EP1430128A2 Micro-rna molecules |
| 06/23/2004 | EP1430125A2 Sperm-specific cation channel, and uses therefor |
| 06/23/2004 | EP1430124A2 Artificial ubiquitous chromatin opening elements (ucoe) |
| 06/23/2004 | EP1430116A2 A packaging complementation cell-line for sv-40 vectors |
| 06/23/2004 | EP1430115A1 Immortilized stem cells |
| 06/23/2004 | EP1430076A2 Polypeptides derived from inducible hsp70 and pharmaceutical compositions containing the same |
| 06/23/2004 | EP1430074A1 Aminoglycoside lipid derivatives for transfection |
| 06/23/2004 | EP1430072A2 Antisense modulation of cholesteryl ester transfer protein expression |
| 06/23/2004 | EP1429797A2 Diagnosis and treatment of malignant neoplasms |
| 06/23/2004 | EP1429689A1 Rational drug therapy device and methods |
| 06/23/2004 | EP1263932A4 Embryonic stem cells and neural progenitor cells derived therefrom |
| 06/23/2004 | EP1171573B1 Arpe-19 as a platform cell line for encapsulated cell-based delivery |
| 06/23/2004 | EP1131411B1 Suppression of xenotransplant rejection |
| 06/23/2004 | EP1032671B1 Mammalian cytokine-like polypeptide-10 |
| 06/23/2004 | EP1003500A4 Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury |
| 06/23/2004 | CN1506117A Antitumor genetic transcription regulating medicine |
| 06/23/2004 | CN1506042A Method and composition for improving skin state using compound from fetal cell and tissue |
| 06/23/2004 | CN1154744C Retroviral vectors that containing none of viral coding sequences |
| 06/23/2004 | CN1154742C Recombinant MVA virus, and the use thereof |
| 06/23/2004 | CN1154738C Noval method for characterization of compounds which stimulate STF-1 expression in pancreatic islet cells |
| 06/22/2004 | US6753424 Conjugates of DNA interacting groups with steroid hormones for use as nucleic acid transfection agents |
| 06/22/2004 | US6753423 For preferentially modulated gene expression in liver and associated tissues |
| 06/22/2004 | US6753419 Used for somatic gene therapy |
| 06/22/2004 | US6753411 Genetic engineering; insertion vector into polypeptides |
| 06/22/2004 | US6753321 Method of modulating neovascularization |
| 06/22/2004 | US6753140 Nucleotide sequences coding preferential polypeptide for use in the treatment of diabetes and eating disorders |
| 06/22/2004 | US6752987 Adenovirus encoding human adenylylcyclase (AC) VI |
| 06/17/2004 | WO2004050886A1 Packaging cell system for eb virus vector |
| 06/17/2004 | WO2004050870A2 Genetic switches for the detection of fusion proteins |
| 06/17/2004 | WO2004050859A2 Homologous recombination in multipotent adult progenitor cells |
| 06/17/2004 | WO2004050844A2 Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases |
| 06/17/2004 | WO2004050829A2 Recombinant double-stranded rna phage, and use of the same |
| 06/17/2004 | WO2004050702A2 Novel ifngamma-like polypeptides |
| 06/17/2004 | WO2004050680A2 Use of spliceosome mediated rna trans-splicing to confer cell selective replication to adenoviruses |
| 06/17/2004 | WO2004050126A2 Compositions for treating or preventing angiogenesis-dependent symptoms |
| 06/17/2004 | WO2004050117A1 Proteins involved in the regulation of energy homeostasis |
| 06/17/2004 | WO2004050112A1 Intratumor administration of heat shock protein and its combination tumor therapy with cell toxin |
| 06/17/2004 | WO2004050027A2 Materials and methods for treating ocular-related disorders |
| 06/17/2004 | WO2004050007A2 Mammalian bt-42 proteins involved in the regulation of energy homeostasis |
| 06/17/2004 | WO2004049964A2 Drug to be introduced tooth or periodontal tissue and apparatus for introducing drug to tooth or periodontal tissue |